Literature DB >> 26975524

A Prescription for "Deprescribing" in Psychiatry.

Swapnil Gupta1, John Daniel Cahill1.   

Abstract

The term "deprescribing," initially coined in geriatric medicine, describes a process of pharmacologic regimen optimization through reduction or cessation of medications for which benefits no longer outweigh risks. Burgeoning rates of polypharmacy, growing appreciation of long-term adverse effects, and a focus on patient-centered practice present specific indications for deprescribing in psychiatry. A strong therapeutic alliance, appropriate timing, and consideration of the meaning of medication for the patient must accompany the following established elements: review of all medications, identification of medications that could be ceased or reduced, collaborative planning of the deprescribing regimen, and provision of review and support to the patient and caregivers. The authors discuss how deprescribing might be adapted for and implemented in psychiatry, identify potential barriers, and make recommendations for future directions.

Entities:  

Mesh:

Year:  2016        PMID: 26975524     DOI: 10.1176/appi.ps.201500359

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  7 in total

1.  The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.

Authors:  Rosa Shapiro-Thompson; Sarah K Fineberg
Journal:  Curr Treat Options Psychiatry       Date:  2022-03-04

2.  Psychotropic Polypharmacy and Antipsychotics in Children: A Survey of Caregiver's Perspectives.

Authors:  Jennifer L McLaren; Erin R Barnett; Stephanie C Acquilano; Milangel T Concepcion Zayas; Robert E Drake; JoAnna K Leyenaar
Journal:  Community Ment Health J       Date:  2021-05-31

3.  Case reports of interprofessional care for clients enrolled in a mental health court.

Authors:  Beth DeJongh; Michael Oldani
Journal:  Ment Health Clin       Date:  2018-11-01

4.  Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior: A Prospective, Multicenter Study in Italy.

Authors:  E di Giacomo; A Stefana; V Candini; G Bianconi; L Canal; M Clerici; G Conte; M T Ferla; L Iozzino; G Sbravati; G Tura; R Micciolo; G de Girolamo
Journal:  Int J Neuropsychopharmacol       Date:  2020-05-27       Impact factor: 5.176

5.  Core Patient-Reported Outcomes (PROs) and PRO Measures (PROMs) for Polypharmacy Medicines Reviews: A Sequential Mixed-Methods Study.

Authors:  Grigorios Kotronoulas; Mark Cooper; Bridget Johnston
Journal:  Patient Prefer Adherence       Date:  2019-12-13       Impact factor: 2.711

6.  Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment.

Authors:  Gail A Edelsohn; Kemal Eren; Meghna Parthasarathy; Neal D Ryan; Amy Herschell
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

Review 7.  The role of trust and hope in antipsychotic medication reviews between GPs and service users a realist review.

Authors:  L M Grünwald; C Duddy; R Byng; N Crellin; J Moncrieff
Journal:  BMC Psychiatry       Date:  2021-08-04       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.